Skip to main content
Premium Trial:

Request an Annual Quote

Quest Launches EGFR Test for Erbitux, Vectibix Users Based on Somalogic's Somamer Technology

Premium

Quest Diagnostics has begun offering a test for measuring free epidermal growth factor receptor using Somalogic's aptamer-based Somamer technology.

The test is designed to measure free EGFR concentration in patients receiving cetuximab or panitumumab – marketed by Bristol-Myers Squibb/Merck/Lilly as Erbitux and by Amgen as Vectibix, respectively – as a surrogate drug efficacy indicator.

Somalogic director of communications Fintan Steele told ProteoMonitor that the Somamer technology appears to distinguish between bound and unbound levels of EGFR in serum better than existing antibodies to the protein, making it potentially useful for measuring these levels.

Steele noted that the EGFR test is not a main focus of Somalogic and Quest's relationship – which has primarily emphasized development of larger diagnostic panels for diseases including lung and pancreatic cancer – but he called it a "proof of concept of the [Somamer] technology."

The Somamer technology uses a modified form of aptamers – single-stranded nucleic acids capable of binding target molecules – for the detection of proteins. The molecules represent an alternative to antibodies for protein discovery and identification, offering a high level of specificity that allows for multiplex arrays significantly larger than is possible using traditional ELISA platforms.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.